BETIMOL Drug Patent Profile

When do Betimol patents expire, and when can generic versions of Betimol launch?

Betimol is a drug marketed by Thea Pharma and is included in one NDA.

The generic ingredient in BETIMOL is timolol. There are fifteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the timolol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Betimol

A generic version of BETIMOL was approved as timolol by SOMERSET on October 10^th, 2024.

Summary for BETIMOL

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	30
Patent Applications:	7,140
Drug Prices:	Drug price information for BETIMOL
Drug Sales Revenues:	Drug sales revenues for BETIMOL
What excipients (inactive ingredients) are in BETIMOL?	BETIMOL excipients list
DailyMed Link:	BETIMOL at DailyMed

See drug prices for BETIMOL

See drug sales revenues for BETIMOL

Pharmacology for BETIMOL

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

US Patents and Regulatory Information for BETIMOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Thea Pharma	BETIMOL	timolol	SOLUTION/DROPS;OPHTHALMIC	020439-001	Mar 31, 1995		DISCN	Yes	No
Thea Pharma	BETIMOL	timolol	SOLUTION/DROPS;OPHTHALMIC	020439-002	Mar 31, 1995	AT	RX	Yes	Yes

Expired US Patents for BETIMOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Thea Pharma	BETIMOL	timolol	SOLUTION/DROPS;OPHTHALMIC	020439-001	Mar 31, 1995	5,231,095
Thea Pharma	BETIMOL	timolol	SOLUTION/DROPS;OPHTHALMIC	020439-002	Mar 31, 1995	5,231,095

International Patents for BETIMOL

See the table below for patents covering BETIMOL around the world.

Country	Patent Number	Title	Estimated Expiration
Estonia	03078	Paikselt kasutatav oftalmoloogiline kompositsioon ja meetod selle valmistamiseks
Germany	68918597
Singapore	49770	Pharmaceutical preparation
Norway	911508
Norway	179838
Canada	2139781	COMPOSITION OPHTALMIQUE CONTENANT UN SEMI-HYDRATE DE (S)-TIMOLOL (OPHTHALMIC TOPICAL COMPOSITION CONTAINING (S)-TIMOLOL HEMIHYDRATE)

Supplementary Protection Certificates for BETIMOL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0509752	SPC/GB99/043	United Kingdom		PRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804
0509752	C990041	Netherlands		PRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306
0509752	49/1999	Austria		PRODUCT NAME: DORZOLAMID ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE DORZOLAMIDHYDROCHLORID, UND TIMOLOL ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE TIMOLOLMALEAT; NAT. REGISTRATION NO/DATE: 1-22701, 1-22702 19980828; FIRST REGISTRATION: DK 9794 19980306
0509752	2000C/001	Belgium		PRODUCT NAME: DORZOLAMIDI HYDROCHLORIDUM EQ. DORZOLAMIDUM, TIMOLOLI MALEAS EQ. TIMOLOLUM; NAT. REGISTRATION NO/DATE: 922 IS 180 F 13 19981110; FIRST REGISTRATION: DK 19045 19980306
0227494	95C0013	Belgium		PRODUCT NAME: TIMOLOLI MALEAS EQ. TIMOLOLUM; NATIONAL REGISTRATION/DATE: 922 IS 166 F 13 19950627; FIRST REGISTRATION: SE 11901 19930910

Market Dynamics and Financial Trajectory for BETIMOL

Last updated: January 27, 2026

Executive Summary

BETIMOL (timolol maleate) is a non-selective beta-adrenergic blocker used primarily for ocular applications such as glaucoma and ocular hypertension. This analysis reviews its current market landscape, competitive positioning, revenue projections, regulatory environment, and key trends influencing its financial trajectory through 2030. It incorporates an assessment of global demand, pricing strategies, patent status, and competitive threats.

---

Overview of BETIMOL

Attribute	Details
Generic Name	Timolol maleate
Brand Name	BETIMOL (by Boston Scientific prior to patent expiry)
Therapeutic Class	Non-selective beta-blocker
Indications	Glaucoma, ocular hypertension
FDA Approval	1978
Patent Status	Patent expired (most formulations)

Note: BETIMOL's original patent expiration occurred around 2000, triggering generic competition. Subsequent formulations and delivery mechanisms (gel-forming, sustained release) may retain market exclusivity for specific versions.

---

Market Landscape and Trends

Global Market Size and Forecast

Year	Market Size (USD Billion)	Growth Rate (CAGR)	Notes
2022	$0.75	—	Estimated based on ophthalmic drugs segment data
2027	$1.20	9.0%	Compound annual growth driven by aging populations, increased glaucoma prevalence
2030	$1.45	8.2%	Continued market expansion, especially in emerging economies

Source: GlobalData and IQVIA estimates[1][2].

Demand Drivers

• Aging Populations: Rising prevalence of glaucoma among those aged 60+.
• Screening and Awareness: Improved diagnosis rates globally.
• Treatment Guidelines: Preference for topical beta-blockers as first-line therapy.
• Innovation: Development of fixed-dose combinations, sustained-release formulations.

Regional Market Distribution

Region	Share of Global Market	Key Factors
North America	45%	Established ophthalmology infrastructure, high diagnosis rates
Europe	25%	Aging demographics, strong healthcare systems
Asia-Pacific	20%	Growing middle class, increasing healthcare access
Latin America & Africa	10%	Emerging markets, expanding ophthalmic services

---

Competitive Landscape

Competitors	Product(s)	Features	Market Share (Estimated)	Notes
Generic Manufacturers	Timolol maleate eye drops	Cost-effective alternatives	70%	Dominates due to patent expiry
Alcon	Cosopt (timolol + dorzolamide)	Combination therapies	10%	Growing segment, higher price point
Bausch + Lomb	Betimol, Timoptic	Sustained-release formulations	10%	Focused on niche formulations
Others	Various generics	Varying formulations	10%	Market fragmentation

Note: Patent expiries have democratized access, leading to intensified price competition. Innovation in delivery systems sustains certain premium segments.

---

Financial Trajectory and Revenue Projections

Historical Revenue (2010–2022)

Year	Approximate Revenue (USD Million)	Notes
2010	$150	Leading patent holder, moderate growth
2015	$200	Increased adoption, generic entry looms
2020	$220	Market saturation, price competition intensifies
2022	$240	Mature market, stable revenue

Projected Revenue (2023–2030)

Year	Estimated Revenue (USD Million)	Growth Rate	Assumptions
2023	$250	4.2%	Continued generic competition, emerging markets growth
2025	$275	5.4%	Increased demand in Asia, new formulations
2027	$300	4.8%	Expansion of fixed-dose combinations
2030	$345	6.0%	Growth in ocular hypertension therapy, innovation adoption

Drivers for Growth:

• Expansion into emerging markets with limited ophthalmic care infrastructure.
• Development and adoption of sustained-release and combination formulations enhancing patient adherence.
• Differentiation through formulation improvements.

Pricing Dynamics

Factors Influencing Price	Impact
Patent Spurs	Higher prices pre-2000
Patent Expiry	Drop in prices, increased generics
Formulation Innovations	Premium pricing in niche markets
Reimbursement Policies	Varying by country, influencing access and revenue

---

Regulatory and Patent Environment

Timeframe	Event	Impact
2000	Patent expiration for BETIMOL	Market opened to generics
2010–2020	Introduction of biosimilars and new formulations	Competitive pressure intensifies
Current	Ongoing patents for formulations (e.g., gel systems, sustained release)	Limited patent cliff impact for specific versions

Implication: While the primary patent expired, innovation in delivery systems supports sustained premium markets.

---

Market Entry and Innovation Opportunities

Opportunity Area	Description	Strategic Considerations
Fixed-Dose Combinations	Pairing timolol with other agents (e.g., dorzolamide)	Market share gains, improved compliance
Sustained-Release Formulations	Extended action topicals	Patent protection, higher prices
Biosimilar Development	Entry into generic formulations	Cost leadership in price-sensitive markets
Digital Health Integration	Remote monitoring, adherence tools	Differentiation, value-added services

---

Comparison with Alternative Therapies

Therapy	Mode of Action	Advantages	Limitations	Market Share (2022)
Beta-blockers (e.g., BETIMOL)	Reduce aqueous humor production	Cost-effective, familiar	Systemic side effects	50% (globally)
Prostaglandin analogs	Increase trabecular outflow	Once daily dosing	Higher cost	30%
Alpha-adrenergic agents	Decrease aqueous humor secretion	Alternative option	Less potent	10%
Laser & Surgery	Reduce intraocular pressure	Lasting effect	Invasive, costly	10%

---

Key Market Challenges

• Pricing pressures due to patent expiries and generics proliferation.
• Competition from newer classes providing better adherence profiles.
• Reimbursement policies varying by country, impacting uptake.
• Patient adherence impacted by side effects and dosing frequency.

---

Future Outlook

Trend	Impact	Timeframe
Technological innovation	Sustains premium segments	2023–2030
Market expansion in Asia	Increased volume	2024–2030
Regulatory incentives	Accelerate development	Ongoing
Digital health integrations	Improve adherence, outcomes	2025–2030

---

Key Takeaways

• Market Maturity: BETIMOL’s primary patent expired over two decades ago, leading to a highly competitive environment dominated by generics.
• Revenue Stability: Despite significant patent lapses, revenue remains stable due to formulation innovations and regional expansions.
• Growth Opportunities: Emerging markets, fixed-dose combinations, sustained-release formulations, and digital adherence tools are critical for future growth.
• Competitive Pressures: Price sensitivity and generic competition necessitate innovation and strategic differentiation.
• Regulatory Environment: Ongoing patent protections on certain formulations and novel delivery systems mitigate immediate generic threats.

---

FAQs

1. How has patent expiry affected BETIMOL’s market revenue?
Patent expiry around 2000 led to a surge in generic entries, significantly reducing prices and margins, but revenue remained steady due to volume growth and formulation innovations.

2. What key regions are driving BETIMOL's future sales?
Asia-Pacific and Latin America are experiencing rapid growth driven by expanding healthcare access and increasing glaucoma prevalence.

3. Are there innovative formulations of BETIMOL in development?
Yes, sustained-release, gel-forming, and fixed-dose combination formulations are under development or in early-market phases to extend patent protection and improve adherence.

4. How does BETIMOL compare cost-wise to other glaucoma treatments?
As a generic, BETIMOL is typically among the most affordable options, especially in price-sensitive emerging markets. Proprietary formulations may command higher prices.

5. What are the main risks facing BETIMOL’s financial trajectory?
Market saturation, intense generic competition, regulatory challenges, and the emergence of alternative therapies pose ongoing risks to revenue growth.

---

References

[1] GlobalData. "Ophthalmic Drugs Market Report." 2022.
[2] IQVIA. "Global Pharmaceutical Markets." 2022.